Agenus strong clinical results, capital transaction

 

BOT/BAL Achieves Breakthrough Response Rates in MSS Cancers — Oral AACR Data Spotlight Pan-Tumor Neoadjuvant Success
Seasoned Leader Onboard to Accelerate BOT/BAL Toward Registration Milestones
Near-Term Capital Transaction Poised to Bolster Liquidity

Agenus is on track to reduce its annualized operating cash burn below $50 million starting in the second half of 2025, supported by recent cost optimization measures enabling the company to direct resources toward ensuring the potential of BOT/BAL is realized. The company is in final stages of an important collaboration which will result in substantial cash infusion.

Conference Call

Date: Monday, May 12th, at 8:30 a.m. ET
To access dial-in numbers, please register here.
Conference ID: 73242

Webcast

A live webcast and replay of the conference call will be accessible on the company’s website at https://investor.agenusbio.com/events-and-presentations.

https://www.stocktitan.net/news/AGEN/agenus-reports-q1-2025-financial-results-and-key-business-56niyf1sftvl.html